Tirzepatide and Kidney Function: The Renal Data

Tirzepatide and Kidney Protection

-55.2% UACR

In the SURMOUNT-2 trial, tirzepatide reduced urine albumin-to-creatinine ratio by 55.2% versus placebo in participants with baseline albuminuria (UACR greater than 30 mg/g).

Heerspink et al., JASN, 2025

Heerspink et al., JASN, 2025

View as image

Tirzepatide (Mounjaro/Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and obesity. While its kidney effects were not the primary endpoint of any trial, renal data from the SURPASS, SURMOUNT, and SUMMIT programs have accumulated rapidly. The pattern is consistent: tirzepatide reduces albuminuria across populations, from type 2 diabetes patients to people with obesity alone, with effects that persist through at least 72 weeks of treatment.^[1][2] But tirzepatide does not yet have a dedicated kidney outcomes trial comparable to semaglutide's FLOW trial. This article examines what the existing data shows, what it does not show, and where the evidence stands relative to other GLP-1 receptor agonists. For the broader GLP-1 kidney story, see GLP-1 Agonists and Kidney Disease: How Weight Loss Drugs Protect Kidneys.

The Clinical Trial Evidence

SURPASS Trials: Type 2 Diabetes

The SURPASS program (SURPASS-1 through SURPASS-5) tested tirzepatide in type 2 diabetes across different comparators (placebo, semaglutide, insulin degludec, insulin glargine). SURPASS-4, which enrolled patients at high cardiovascular risk, provided the first signal of kidney benefit.

Apperloo et al. (2025) published a pooled post hoc analysis of all five SURPASS trials (6,263 participants). The key findings:^[1]

• UACR reduction vs. all comparators: Tirzepatide 5 mg reduced UACR by 19.3%, 10 mg by 22.0%, and 15 mg by 26.3% at weeks 40/42
• Dose-response relationship: A clear gradient from 5 mg to 15 mg, suggesting the effect is not simply binary
• Consistent across comparators: Similar UACR reductions whether compared to placebo, active comparators (semaglutide 1 mg), or insulin
• Greater effect in albuminuric patients: Among those with UACR greater than 30 mg/g at baseline, the highest tirzepatide dose outperformed semaglutide 1 mg
• No eGFR change: No significant difference in estimated glomerular filtration rate between tirzepatide and comparators at week 40/42

The pooled analysis also performed mediation analysis, finding that approximately half of the UACR reduction was attributable to weight loss, with the remainder potentially reflecting direct renal effects. This is a critical finding because it suggests tirzepatide may protect kidneys through both weight-dependent and weight-independent mechanisms.

SURMOUNT Trials: Obesity With and Without Diabetes

The SURMOUNT program tested tirzepatide in obesity, expanding the kidney data beyond diabetes. Heerspink et al. (2025) analyzed kidney parameters from SURMOUNT-1 (2,539 participants with obesity, no diabetes) and SURMOUNT-2 (938 participants with obesity and type 2 diabetes) through 72 weeks.^[2]

SURMOUNT-1 (no diabetes):

• UACR reduction vs. placebo at week 72: 8.4% (overall population)
• UACR reduction in those with baseline UACR greater than 30 mg/g: 42.3%
• Cystatin C-based eGFR increased by 3.2 mL/min/1.73 m2 versus placebo
• Creatinine-cystatin C-based eGFR increased by 1.9 mL/min/1.73 m2

SURMOUNT-2 (with diabetes):

• UACR reduction vs. placebo at week 72: 31.1% (overall population)
• UACR reduction in those with baseline UACR greater than 30 mg/g: 55.2%
• No significant between-group difference in cystatin C-based eGFR

The difference between the two populations is instructive. People with diabetes and higher baseline albuminuria showed much larger UACR reductions (55.2% vs. 42.3% in the albuminuric subgroups). This pattern, where the renal benefit scales with the degree of baseline kidney involvement, is consistent with what has been observed with SGLT2 inhibitors and semaglutide. It also has practical implications: patients who stand to benefit most from kidney protection (those with existing albuminuria) appear to receive the largest renal benefit from tirzepatide.

The SURMOUNT data is also notable because it extends kidney findings beyond diabetes. SURMOUNT-1 enrolled participants with obesity but without type 2 diabetes, and still showed significant UACR reduction (42.3% in the albuminuric subgroup) and improved cystatin C-based eGFR (+3.2 mL/min/1.73 m2). This suggests the kidney-protective effects of tirzepatide are not solely mediated through glycemic improvement, which is expected given the weight-dependent mechanisms described below. Obesity-related kidney disease is an increasingly recognized entity affecting an estimated 24-33% of people with obesity, making this finding clinically relevant for a large population currently undertreated from a nephrology perspective.

SUMMIT Trial: Heart Failure Context

The SUMMIT trial tested tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity. Packer et al. (2025) reported the renal outcomes in a dedicated analysis of CKD-HFpEF interplay.^[3]

An important methodological nuance emerged: tirzepatide produced an initial dip in creatinine-based eGFR at 12 weeks, but no dip in cystatin C-based eGFR. By 52 weeks, cystatin C eGFR improved in all patients, and creatinine-based eGFR improved specifically in patients with CKD. The SUMMIT analysis also examined the interaction between CKD severity and tirzepatide's cardiac benefits, finding that tirzepatide's effects on heart failure outcomes were preserved in patients with CKD stages 3a-3b, an important finding because CKD and HFpEF frequently coexist and share pathophysiological mechanisms including fluid retention, systemic inflammation, and endothelial dysfunction.

The creatinine-cystatin C divergence is not unique to tirzepatide. Weight loss from any cause increases serum creatinine (because creatinine is produced by muscle, and weight loss reduces muscle mass), which makes creatinine-based eGFR appear to decline even when true kidney function is stable or improving. Cystatin C is not affected by muscle mass and provides a more accurate assessment of filtration in the weight-loss context. This measurement artifact has implications for clinical monitoring: creatinine-based eGFR declines in patients on tirzepatide do not necessarily indicate kidney damage.

Prospective CKD Data

Oe et al. (2025) published a prospective observational study specifically in patients with type 2 diabetes and established chronic kidney disease. Over the study period, tirzepatide improved HbA1c and body weight without worsening eGFR, providing the most direct evidence to date that tirzepatide is safe and effective in patients with existing kidney disease.^[4]

Systematic Review

Kamrul-Hasan et al. (2025) conducted a systematic review and meta-analysis of 21 studies examining tirzepatide's renal effects. The analysis confirmed consistent UACR reduction without adverse eGFR changes across both diabetic and non-diabetic populations, providing the strongest aggregate evidence to date.^[5]

Proposed Mechanisms

Tirzepatide's kidney effects likely operate through multiple pathways.

Weight-Dependent Mechanisms

Approximately 50% of the albuminuria reduction appears weight-mediated, based on mediation analysis from the SURPASS pooled data. Obesity itself damages kidneys through several interconnected pathways: glomerular hyperfiltration (the kidney works harder to filter blood in larger bodies), increased intraglomerular pressure, compression of renal parenchyma by perinephric and renal sinus fat deposits, adipokine-mediated inflammation (leptin, resistin, and other fat-derived signals drive glomerular injury), and insulin resistance that promotes mesangial expansion and basement membrane thickening.

Weight loss reverses these processes regardless of how it is achieved. Bariatric surgery studies have shown that substantial weight loss reduces albuminuria by 40-70% and slows eGFR decline in obese CKD patients. Tirzepatide produces average weight loss of 15-22% in obesity trials, exceeding what most pharmacological interventions achieve and approaching bariatric surgery levels. The kidney benefits that track with weight loss are therefore expected and represent a real therapeutic effect, even if they are not specific to tirzepatide's receptor pharmacology.

GLP-1 Receptor-Mediated Effects

GLP-1 receptors are expressed in the kidney, including in the proximal tubule, juxtaglomerular apparatus, and glomerular vasculature. GLP-1 receptor activation in the kidney produces several protective effects:

• Natriuresis and hemodynamic regulation: GLP-1 agonists inhibit the sodium-hydrogen exchanger NHE3 in the proximal tubule, increasing sodium excretion. This reduces tubuloglomerular feedback-mediated hyperfiltration and decreases intraglomerular pressure, the same hemodynamic mechanism by which SGLT2 inhibitors protect the kidney.
• Anti-inflammatory effects: GLP-1 receptor activation suppresses NF-kappaB signaling in mesangial cells and podocytes, reducing inflammatory cytokine production and immune cell infiltration in the glomerulus
• Tubular albumin handling: GLP-1 receptor activation improves megalin-mediated albumin reabsorption in the proximal tubule, directly reducing albuminuria
• Oxidative stress reduction: GLP-1 signaling activates antioxidant defense pathways (Nrf2/HO-1) in renal cells, reducing reactive oxygen species that damage the glomerular filtration barrier

These effects are shared with semaglutide, liraglutide, and other GLP-1 agonists. The question for tirzepatide is whether GIP co-agonism adds renal protection on top of these GLP-1 effects.

GIP Receptor-Mediated Effects

Tirzepatide's unique feature is dual GIP/GLP-1 agonism. GIP receptors are located in adipose tissue surrounding the kidney (perinephric and perirenal fat), in bone, and in the central nervous system. Targeting GIP receptors in perinephric fat may suppress proinflammatory cytokine production (TNF-alpha, IL-6, MCP-1) in the renal microenvironment, potentially providing kidney protection beyond what GLP-1 agonism alone achieves. GIP receptor activation also enhances insulin sensitivity in adipose tissue, which may indirectly reduce lipotoxic kidney damage. This is the least-established mechanism but is biologically plausible and may explain why tirzepatide showed numerically larger UACR reductions than semaglutide 1 mg in the SURPASS pooled analysis for patients with elevated baseline albuminuria. See GLP-1 and GIP: The Two Incretins and Why They Matter for more on GIP receptor biology.

Direct Anti-Inflammatory and Antioxidant Effects

Animal studies have identified specific molecular pathways. Tian et al. (2025) showed tirzepatide normalized diabetic nephropathy in db/db mice via PI3K/AKT-mediated suppression of oxidative stress.^[6] Yang et al. (2025) demonstrated that tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy through the IL-17 signaling pathway.^[7] Ma et al. (2025) identified a novel mechanism: tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease, suggesting gut-kidney axis effects.^[8]

In a head-to-head comparison of liraglutide, tirzepatide, and retatrutide (a triple GLP-1/GIP/glucagon agonist) in diabetic mice, Ma et al. (2025) found all three protected against diabetic kidney disease, but with different efficacy profiles, suggesting the specific receptor agonism pattern influences the degree of renal protection.^[9]

How Tirzepatide Compares to Semaglutide

The most relevant comparison is semaglutide, which has the FLOW trial, the first dedicated kidney outcomes trial for a GLP-1 receptor agonist. The FLOW trial (Perkovic et al., NEJM, 2024) randomized 3,533 patients with type 2 diabetes and CKD to semaglutide 1 mg weekly or placebo. It was stopped early for efficacy: semaglutide reduced the risk of the primary composite kidney outcome (sustained eGFR decline of at least 50%, kidney failure, kidney-related death, or cardiovascular death) by 24% (hazard ratio 0.76).^[10] For a detailed analysis, see The FLOW Trial: Semaglutide's Kidney Protection Results.

Tirzepatide does not have equivalent data. The differences in evidence quality are substantial:

The SURPASS-CVOT trial (NCT05536804, ongoing) includes kidney endpoints but is primarily a cardiovascular outcomes trial comparing tirzepatide to dulaglutide in patients with type 2 diabetes at high cardiovascular risk. Early subgroup data from SURPASS-CVOT presented at Kidney Week 2025 showed tirzepatide reduced the risk of a four-component composite kidney outcome by 33% compared to dulaglutide at 36 months, with eGFR preservation of 4.1 mL/min/1.73 m2 and UACR reduction of 24.6% versus dulaglutide in the very high-risk CKD subgroup. These are the closest data to hard kidney outcomes for tirzepatide, but they compare to an active GLP-1 agonist (dulaglutide), not placebo, and are preliminary.

A dedicated tirzepatide kidney outcomes trial (comparable in design to FLOW) has not been announced. Until one is completed, tirzepatide's kidney data remains secondary/post hoc or versus active comparator, which limits the strength of conclusions about kidney protection as a standalone benefit. The totality of evidence, however, is directionally consistent and suggests renal protection that may be at least comparable to, and potentially greater than, single GLP-1 agonists in the albuminuric subpopulation.

Safety Considerations

Acute Kidney Injury Risk

A case report by Almansour et al. (2025) documented acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities.^[11] The mechanism was likely dehydration from GI side effects (nausea, vomiting) rather than direct nephrotoxicity. This risk is shared with all GLP-1 receptor agonists and is dose-titration dependent.

This case highlights that the primary renal safety concern with tirzepatide is not direct nephrotoxicity but dehydration-mediated kidney injury, which is preventable with appropriate clinical management.

Risk factors for AKI with incretin-based therapies include:

• Pre-existing CKD
• Concurrent diuretic use
• Inadequate fluid intake during GI side effects
• Rapid dose escalation
• Advanced age

The systematic review by Kamrul-Hasan et al. confirmed that at standard doses with appropriate titration, tirzepatide does not increase AKI risk and actually improves renal safety markers overall.^[5]

The Creatinine Measurement Problem

As noted in the SUMMIT analysis, weight loss confounds creatinine-based eGFR. Clinicians monitoring kidney function in patients on tirzepatide should be aware that:

• Creatinine-based eGFR may decline in the first 12 weeks even if true kidney function is stable
• Cystatin C-based eGFR provides a more accurate assessment during weight loss
• A stable or rising cystatin C-based eGFR alongside falling creatinine-based eGFR is expected and not cause for concern
• Significant declines in both measurements warrant clinical evaluation

This is not a safety problem with tirzepatide; it is a measurement artifact. But it can lead to unnecessary medication discontinuation if not recognized. For the broader implications of GLP-1 drugs and albuminuria, see GLP-1 Drugs and Albuminuria: Reducing the Early Sign of Kidney Damage.

What the Evidence Does and Does Not Support

Supported by clinical data:

• Tirzepatide consistently reduces albuminuria across type 2 diabetes and obesity populations
• The effect is dose-dependent (5 mg less than 10 mg less than 15 mg)
• Approximately half the effect is weight-mediated; the other half may be direct
• Tirzepatide does not worsen eGFR (by cystatin C measurement) and may improve it
• The effect is consistent with or without concurrent RAAS inhibitor or SGLT2 inhibitor use
• Animal studies identify specific anti-inflammatory and antioxidant pathways

Not yet established:

• Whether tirzepatide prevents hard kidney outcomes (kidney failure, dialysis, transplant)
• Whether tirzepatide's kidney effects are superior to, equivalent to, or less than semaglutide's
• Whether the GIP receptor component provides additional kidney protection beyond GLP-1 alone
• Whether the benefits persist after discontinuation (weight regain after GLP-1 agonist cessation is well-documented and may reverse weight-dependent kidney benefits)
• Long-term safety beyond 72 weeks in CKD populations
• The optimal tirzepatide dose for kidney protection (the dose-response for albuminuria may differ from the dose-response for weight loss)
• Whether combination with SGLT2 inhibitors provides additive kidney protection (SGLT2 inhibitors and GLP-1 agonists protect kidneys through partially overlapping and partially distinct mechanisms)

The SGLT2 Inhibitor Comparison

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are the current standard of care for kidney protection in diabetic and non-diabetic CKD, with multiple dedicated kidney outcomes trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY). Tirzepatide's kidney effects should be understood in this context. The SURPASS pooled analysis found that tirzepatide's UACR reduction was consistent regardless of concurrent SGLT2 inhibitor use, suggesting the mechanisms may be complementary rather than redundant. A clinical scenario where both a SGLT2 inhibitor and tirzepatide are prescribed for a patient with type 2 diabetes, obesity, and CKD is increasingly common, and the available data suggests this combination is both safe and potentially additive for kidney protection, though dedicated combination studies have not been conducted.

The gap between albuminuria reduction and hard kidney outcomes is important. Albuminuria is a validated surrogate marker for kidney disease progression, and drugs that reduce albuminuria generally slow CKD progression. The FDA has accepted albuminuria as a reasonably likely surrogate endpoint for accelerated approval in CKD. But surrogate markers are not guarantees; the history of medicine includes examples where drugs improved surrogate markers but failed to improve clinical outcomes. The FLOW trial closed this gap for semaglutide by demonstrating hard outcomes. Tirzepatide needs equivalent data. For the broader evidence on how GLP-1 drugs protect kidneys, including the cardiovascular trials that first suggested renal benefits, see GLP-1 Drugs and Heart Disease: What the Cardiovascular Trials Show.

The Bottom Line

Tirzepatide reduces albuminuria by 19-55% depending on population and baseline kidney involvement, with consistent effects across the SURPASS (diabetes), SURMOUNT (obesity), and SUMMIT (heart failure) programs. Approximately half of this effect appears weight-mediated, with the remainder potentially reflecting direct renal protection through GLP-1 and GIP receptor pathways. Animal studies identify PI3K/AKT, IL-17, and gut microbiota mechanisms. However, tirzepatide lacks a dedicated kidney outcomes trial with hard endpoints. Until such data exists, semaglutide (with the FLOW trial demonstrating 24% reduction in composite kidney outcomes) has stronger evidence for kidney protection as a standalone benefit.

Frequently Asked Questions

Does tirzepatide protect the kidneys?

Tirzepatide reduces albuminuria (a marker of kidney damage) by 19-55% across clinical trials, with larger effects in people who already have elevated albumin in their urine. A 2025 pooled analysis of the SURPASS-1 through SURPASS-5 trials showed dose-dependent UACR reductions of 19.3% (5 mg), 22.0% (10 mg), and 26.3% (15 mg) versus comparators. However, no dedicated kidney outcomes trial has demonstrated that tirzepatide prevents kidney failure, dialysis, or other hard endpoints. The data supports kidney-protective effects but not confirmed kidney disease prevention.

How does tirzepatide compare to semaglutide for kidney protection?

Semaglutide has stronger kidney evidence because of the FLOW trial (NEJM, 2024), which demonstrated a 24% reduction in composite kidney outcomes in 3,533 patients with established CKD and type 2 diabetes. Tirzepatide's kidney data comes from post hoc analyses of diabetes and obesity trials, not a dedicated kidney trial. In the SURPASS pooled analysis, the highest tirzepatide dose outperformed semaglutide 1 mg for albuminuria reduction in people with elevated UACR, but head-to-head kidney outcomes data does not exist.

Can tirzepatide cause kidney damage?

At standard doses with appropriate titration, tirzepatide does not cause kidney damage. A 2025 systematic review of 21 studies confirmed no adverse effects on eGFR. However, GI side effects (nausea, vomiting) can cause dehydration, which in rare cases may trigger acute kidney injury, particularly in patients with pre-existing CKD, concurrent diuretic use, or inadequate fluid intake. Rapid dose escalation increases this risk. Creatinine-based eGFR may appear to decline during treatment due to weight-loss-related muscle mass reduction, not actual kidney damage.

How does tirzepatide reduce albuminuria?

Mediation analysis from the SURPASS trials suggests approximately 50% of the albuminuria reduction is weight-related. The remaining effect likely involves direct mechanisms: reduced intraglomerular pressure, suppression of renal inflammation via GLP-1 receptors in the kidney, potential anti-inflammatory effects through GIP receptors in perinephric adipose tissue, and improved tubular albumin reabsorption. Animal studies have identified PI3K/AKT pathway activation and IL-17 signaling suppression as specific molecular mechanisms.

Is tirzepatide safe to use with kidney disease?

A prospective 2025 observational study by Oe et al. specifically in patients with type 2 diabetes and established CKD showed tirzepatide improved HbA1c and body weight without worsening eGFR. The SUMMIT trial included HFpEF patients with CKD and found tirzepatide improved cystatin C-based eGFR at 52 weeks in this subgroup. Standard dose titration and adequate hydration are essential, particularly in patients with lower baseline kidney function or concurrent diuretic therapy.

Why does creatinine eGFR drop on tirzepatide?

Creatinine is produced by muscle. When tirzepatide causes weight loss (average 15-22% in obesity trials), muscle mass decreases, serum creatinine rises, and creatinine-based eGFR appears to decline. This is a measurement artifact, not kidney damage. In the SUMMIT trial, creatinine-based eGFR dipped at 12 weeks while cystatin C-based eGFR (which is not affected by muscle mass) remained stable. Clinicians monitoring kidney function during treatment should use cystatin C-based measurements when possible.